Bubs Australia Secures Permanent FDA Approval for Three Infant Formula Products in US Market
核心洞察
Bubs Australia (搜索) received permanent FDA authorization to sell three infant formula products—Bubs Goat (搜索), Bubs 365 Day Grass Fed (搜索), and Bubs Essential (搜索)—in the United States.
The approval positions Bubs as the only Australian infant formula brand and one of a limited number of international manufacturers permitted in the highly regulated US market.
Shares surged as much as 45% intraday to A$0.145, their strongest gain since late-May 2022, before closing 30% higher at their highest level since mid-February.
Bubs Australia (搜索) has secured permanent regulatory authorization from the United States Food and Drug Administration (FDA) to sell three of its core infant formula products in the United States, marking the final step in confirming that the company's products, manufacturing systems, and scientific evidence have fully satisfied US regulatory requirements for infant consumption.
The approved products consist of Bubs Goat (搜索), Bubs 365 Day Grass Fed (搜索), and Bubs Essential (搜索). Bubs stated that the final FDA approval strengthens the company's competitive position as the only Australian infant formula brand, and one of only a limited number of international manufacturers permitted to participate in the highly regulated US consumer category.
The announcement triggered a sharp rally in the company's shares. The stock surged as much as 45% to A$0.145 during the session, its strongest intraday percentage gain since late-May 2022, before closing 30% higher at its highest close since mid-February. In afternoon trading, shares jumped 35% to 13 cents.
Strategic Positioning in the US Market
The FDA authorization places Bubs among a limited number of international manufacturers permitted to supply the US infant formula market. Following the approval, the firm is also evaluating an entry into the US private label infant nutrition segment.
The approval comes amid tighter regulations and supply chain disruptions for infant nutrition companies in Australia and New Zealand. New Zealand-based dairy firm a2 Milk (搜索) said in its annual results last month that supply constraints hurt earnings, highlighting the operational and regulatory complexities facing companies in the sector.
Financial Outlook
Last month, Bubs reported an annual EBITDA loss of A$1.8 million ($1.30 million). However, the company said it expects a stronger first half in 2027, supported by growing demand in the US, a key market in its strategy to diversify beyond China.